ABCL vs ELVN: stock comparison and AI forecast
Abcellera Biologics Inc. (ABCL) and Enliven Therapeutics, Inc. (ELVN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABCL Abcellera Biologics Inc.
- Price
- $12.18 +161.4% · 6M
- Market Cap
- $3.73B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
ELVN Enliven Therapeutics, Inc.
- Market Cap
- $3.28B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ABCL is 1.1 times larger than ELVN by market capitalization ($3.73B against $3.28B).
- ABCL carries 0.46 times debt per unit of equity, against 0.02 times for ELVN.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABCL | ELVN |
|---|---|---|
| Market Cap | $3.73B | $3.28B |
| P/B Ratio | 4.17x | 3.67x |
| EPS | $-0.55 | $-1.83 |
| Book Value/Share | $2.92 | $12.22 |
| Revenue/Share | $0.23 | – |
| FCF/Share | $-0.39 | $-0.91 |
Profitability & Margins
| Metric | ABCL | ELVN |
|---|---|---|
| ROE | -18.4% | -11.8% |
| ROA | -12.6% | -11.6% |
| ROIC | -17.9% | -13.9% |
| Operating Margin | -319.8% | – |
| Net Margin | -233.9% | – |
| EBT Margin | -279.5% | – |
| Tax Rate | 16.3% | 0.0% |
Financial Health
| Metric | ABCL | ELVN |
|---|---|---|
| Current Ratio | 12.77x | 64.07x |
| Quick Ratio | 12.63x | – |
| D/E Ratio | 0.46x | 0.02x |
| Financial Leverage | 1.46x | 1.02x |
| Working Capital | $626M | $893M |
Cash Flow
| Metric | ABCL | ELVN |
|---|---|---|
| Operating Cash Flow | -$95M | -$67M |
| Free Cash Flow | -$120M | -$67M |
| Capital Spending | -$25M | -$100K |
| FCF/Sales | -170.0% | – |
| CapEx/Sales | 35.1% | – |
Operational Efficiency
| Metric | ABCL | ELVN |
|---|---|---|
| Asset Turnover | 0.05x | – |
| Receivables Turnover | 1.8x | – |
| Days Sales Outstanding | 199 days | – |
Income Statement
| Metric | ABCL | ELVN |
|---|---|---|
| Total Revenue | $70M | – |
| Operating Income | -$225M | -$124M |
| Net Income | -$165M | -$106M |
| R&D Expense | $198M | $89M |
| SG&A Expense | $173M | – |
Dividend & Shareholder Information
| Metric | ABCL | ELVN |
|---|---|---|
| Shares Outstanding | 307M | 73M |
ABCL vs ELVN: stock comparison and AI forecast
Which is bigger, ABCL or ELVN?
ABCL is 1.1 times larger than ELVN by market capitalization ($3.73B against $3.28B).
Which one does Intratio's AI model rank higher, ABCL or ELVN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.